This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsLIDDS（LIDDS）株式概要ドラッグ・デリバリー企業であるLIDDS AB（publish）は、スウェーデンで、がんやその他の疾患の治療のためにNanoZolid独自技術に基づく医薬品を開発している。 詳細LIDDS ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6報酬過去5年間の収益は年間20.3%増加しました。 リスク分析Swedish市場と比較して、過去 3 か月間の株価の変動が非常に大きいキャッシュランウェイが1年未満である 収益が 100 万ドル未満 ( SEK0 )意味のある時価総額がありません ( SEK3M )すべてのリスクチェックを見るLIDDS Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueSEK Current PriceSEK 0.025該当なし内在価値ディスカウントEst. Revenue$PastFuture-41m8m2016201920222025202620282031Revenue SEK 0.1Earnings SEK 0.02AdvancedSet Fair ValueView all narrativesLIDDS AB (publ) 競合他社Nidhogg Resources HoldingSymbol: NGM:NIDHOGMarket cap: SEK 3.8mIsofol MedicalSymbol: OM:ISOFOLMarket cap: SEK 231.7mLipigon PharmaceuticalsSymbol: OM:LPGOMarket cap: SEK 908.9kPharmaLundensisSymbol: NGM:PHALMarket cap: SEK 15.3m価格と性能株価の高値、安値、推移の概要LIDDS過去の株価現在の株価SEK 0.02552週高値SEK 0.1952週安値SEK 0.01ベータ-0.271ヶ月の変化44.71%3ヶ月変化-59.00%1年変化-87.05%3年間の変化-98.34%5年間の変化-99.83%IPOからの変化-99.78%最新ニュースお知らせ • Nov 20LIDDS AB (publ) to Report Fiscal Year 2025 Final Results on May 06, 2026LIDDS AB (publ) announced that they will report fiscal year 2025 final results on May 06, 2026Reported Earnings • Sep 03First half 2025 earnings released: kr0.015 loss per share (vs kr0.02 loss in 1H 2024)First half 2025 results: kr0.015 loss per share (improved from kr0.02 loss in 1H 2024). Net loss: kr2.04m (loss narrowed 15% from 1H 2024).お知らせ • Sep 03LIDDS AB (publ) to Report Fiscal Year 2025 Results on Feb 19, 2026LIDDS AB (publ) announced that they will report fiscal year 2025 results on Feb 19, 2026お知らせ • Apr 26LIDDS AB (publ), Annual General Meeting, May 28, 2025LIDDS AB (publ), Annual General Meeting, May 28, 2025, at 10:00 W. Europe Standard Time. Location: at excore`s premises, at kungsportsavenyen 22, 411 36 gothenburg Swedenお知らせ • Feb 20+ 2 more updatesLIDDS AB (publ) to Report Q1, 2025 Results on May 29, 2025LIDDS AB (publ) announced that they will report Q1, 2025 results on May 29, 2025お知らせ • Nov 22LIDDS AB (publ) to Report Fiscal Year 2024 Final Results on May 06, 2025LIDDS AB (publ) announced that they will report fiscal year 2024 final results on May 06, 2025最新情報をもっと見るRecent updatesお知らせ • Nov 20LIDDS AB (publ) to Report Fiscal Year 2025 Final Results on May 06, 2026LIDDS AB (publ) announced that they will report fiscal year 2025 final results on May 06, 2026Reported Earnings • Sep 03First half 2025 earnings released: kr0.015 loss per share (vs kr0.02 loss in 1H 2024)First half 2025 results: kr0.015 loss per share (improved from kr0.02 loss in 1H 2024). Net loss: kr2.04m (loss narrowed 15% from 1H 2024).お知らせ • Sep 03LIDDS AB (publ) to Report Fiscal Year 2025 Results on Feb 19, 2026LIDDS AB (publ) announced that they will report fiscal year 2025 results on Feb 19, 2026お知らせ • Apr 26LIDDS AB (publ), Annual General Meeting, May 28, 2025LIDDS AB (publ), Annual General Meeting, May 28, 2025, at 10:00 W. Europe Standard Time. Location: at excore`s premises, at kungsportsavenyen 22, 411 36 gothenburg Swedenお知らせ • Feb 20+ 2 more updatesLIDDS AB (publ) to Report Q1, 2025 Results on May 29, 2025LIDDS AB (publ) announced that they will report Q1, 2025 results on May 29, 2025お知らせ • Nov 22LIDDS AB (publ) to Report Fiscal Year 2024 Final Results on May 06, 2025LIDDS AB (publ) announced that they will report fiscal year 2024 final results on May 06, 2025お知らせ • Aug 28LIDDS AB (publ) to Report Fiscal Year 2024 Results on Feb 20, 2025LIDDS AB (publ) announced that they will report fiscal year 2024 results on Feb 20, 2025お知らせ • May 31LIDDS AB (publ) to Report Nine Months, 2024 Results on Nov 21, 2024LIDDS AB (publ) announced that they will report nine months, 2024 results on Nov 21, 2024お知らせ • May 29LIDDS AB (publ) to Report First Half, 2024 Results on Aug 28, 2024LIDDS AB (publ) announced that they will report first half, 2024 results on Aug 28, 2024お知らせ • May 15+ 1 more updateLIDDS AB (publ) Announces CFO Changes, Effective 1 September 2024The Board of Directors of LIDDS AB (publ) appointed Mats Wiking as new CFO from 1 September 2024. Mats Wiking has long financial experience as finance director, controller and business developer from both small and medium sized companies and has the last few years mainly been working with company transactions. Current CFO Jenni Björnulfson will assume a position in another company but will continue in her roles until 1 September 2024 to ensure a smooth transition to Mats Wiking.New Risk • May 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 100% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr27m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr22.7m market cap, or US$2.09m).お知らせ • Apr 19LIDDS AB (publ), Annual General Meeting, May 27, 2024LIDDS AB (publ), Annual General Meeting, May 27, 2024.お知らせ • Mar 22LIDDS AB (publ) (OM:LIDDS) completed the acquisition of Noviga Research AB.LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB on January 29, 2024. The acquisition is subject to approval by the general meeting of LIDDS. The Board of Directors of LIDDS will convene an Extraordinary General Meeting to be held on 27 February 2024. The purchase price consists of newly issued shares in LIDDS in a ratio of 1:1, which means that the number of shares in LIDDS after the transaction amounts to 136,463,326 and value of the transaction is approximately SEK 16.2 million. As of February 27, 2024, LIDDS AB shareholders approved the transaction. LIDDS AB (publ) (OM:LIDDS) completed the acquisition of Noviga Research AB on March 21, 2024.お知らせ • Jan 30LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB.LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB on January 29, 2024. The acquisition is subject to approval by the general meeting of LIDDS. The Board of Directors of LIDDS will convene an Extraordinary General Meeting to be held on 27 February 2024. The purchase price consists of newly issued shares in LIDDS in a ratio of 1:1, which means that the number of shares in LIDDS after the transaction amounts to 136,463,326 and value of the transaction is approximately SEK 16.2 million.お知らせ • Jan 09LIDDS AB (publ) Approves Board ElectionsLIDDS AB (publ) at its EGN held on January 9, 2024 approved election of Daniel Lifveredson, Torbjörn Browall and Lars-Inge Sjöqvist as ordinary board members, and Bengt Viterius as deputy board member. Daniel Lifveredson was elected as Chairman of the Board.お知らせ • Dec 15LIDDS AB (publ) to Report Fiscal Year 2023 Final Results on Apr 23, 2024LIDDS AB (publ) announced that they will report fiscal year 2023 final results at 12:00 PM, Central European Standard Time on Apr 23, 2024お知らせ • Dec 07Lidds AB (Publ) Announces Resignation of Daniel Lifveredson from Board of DirectorsLIDDS AB (publ) announces that Daniel Lifveredson has informed the company that he is leaving the board at his own request. The decision is based on disagreement about the company's strategic direction. The company's board therefore consists of Pontus Ottosson (chairman), David Bejker and Johan Lund. According to LIDDS' articles of association, the board must consist of a minimum of three and a maximum of ten members, and the board thus fulfills the requirements of the articles of association also after Daniel Lifveredson's resignation.お知らせ • Nov 29+ 1 more updateLIDDS AB (publ) to Report Q1, 2024 Results on May 15, 2024LIDDS AB (publ) announced that they will report Q1, 2024 results on May 15, 2024Reported Earnings • Aug 31First half 2023 earnings released: kr0.29 loss per share (vs kr0.58 loss in 1H 2022)First half 2023 results: kr0.29 loss per share (improved from kr0.58 loss in 1H 2022). Net loss: kr17.0m (loss narrowed 14% from 1H 2022). Revenue is expected to decline by 43% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Sweden are expected to grow by 25%.お知らせ • Aug 01LIDDS AB (publ) Announces CEO ChangesLIDDS AB (publ) announced that Matthew Lindon will assume the role of acting Chief Executive Officer for LIDDS, effective August 1st, 2023, succeeding Anders Månsson. In addition to his role as Chief Scientific Officer for LIDDS, Matthew Lindon will take over the role as CEO on an interim basis from August 1st. Matthew joined LIDDS as CSO in March 2022 with over 20 years of drug discovery and development experience in global pharmaceutical R&D from AstraZeneca, GlaxoSmithKline and Merck. Over the last twelve months he has worked closely with out-going CEO, Anders Månsson to focus LIDDS' business and drive forward a strong business development strategy.Anders will remain with LIDDS until August 31st to ensure a smooth transition.New Risk • Jul 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr40m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr40m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (96% increase in shares outstanding). Revenue is less than US$1m (kr1.3m revenue, or US$123k). Market cap is less than US$10m (kr33.0m market cap, or US$3.06m).Reported Earnings • May 30First quarter 2023 earnings released: kr0.29 loss per share (vs kr0.29 loss in 1Q 2022)First quarter 2023 results: kr0.29 loss per share. Net loss: kr9.63m (loss narrowed 1.3% from 1Q 2022). Revenue is expected to decline by 17% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Sweden are expected to grow by 26%.Reported Earnings • Mar 14Full year 2022 earnings released: kr1.07 loss per share (vs kr1.16 loss in FY 2021)Full year 2022 results: kr1.07 loss per share (improved from kr1.16 loss in FY 2021). Net loss: kr36.9m (loss narrowed 1.1% from FY 2021). Revenue is expected to decline by 1.8% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Sweden are expected to grow by 19%. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.お知らせ • Dec 09LIDDS AB (publ) to Report Fiscal Year 2022 Results on Apr 25, 2023LIDDS AB (publ) announced that they will report fiscal year 2022 results at 12:00 PM, Central European Standard Time on Apr 25, 2023Reported Earnings • Nov 29Third quarter 2022 earnings released: kr0.23 loss per share (vs kr0.26 loss in 3Q 2021)Third quarter 2022 results: kr0.23 loss per share. Revenue: kr1.19m (up 176% from 3Q 2021). Net loss: kr8.09m (loss widened 3.6% from 3Q 2021).Reported Earnings • Aug 29Second quarter 2022 earnings released: kr0.29 loss per share (vs kr0.32 loss in 2Q 2021)Second quarter 2022 results: kr0.29 loss per share. Revenue: kr254.0k (up 71% from 2Q 2021). Net loss: kr9.91m (loss widened 1.5% from 2Q 2021).お知らせ • Aug 26LIDDS AB (publ) to Report Fiscal Year 2022 Results on Feb 24, 2023LIDDS AB (publ) announced that they will report fiscal year 2022 results on Feb 24, 2023Board Change • Jul 31High number of new directorsIndependent Director Max Mitteregger was the last director to join the board, commencing their role in 2022.お知らせ • Jul 16LIDDS AB (publ) Announces CEO ChangesLIDDS AB (publ) announced that Anders Månsson will assume the role of Chief Executive Officer for LIDDS, effective September 1st 2022 succeeding Nina Herne. Anders Månsson has broad experience from leading roles both in the biotech sector and in larger multinational pharmaceutical companies in an international setting over 25 years. His substantial experience in business development from serving as e.g VP & Head of Global Business Development in LEO Pharma will be important for LIDDS in driving the value of current and future collaborations. Anders also has considerable experience from sales & marketing; he has been the Managing Director of a subsidiary in Ferring Pharmaceuticals, and he has headed a major global business unit in LEO Pharma. His experience also includes board-level and executive appointments in biotech companies, and most recently Anders was the CEO of RhoVac. Anders will join LIDDS September 1, 2022. Nina will remain as CEO until Anders is in place to secure a smooth transition. Nina is leaving LIDDS due to personal reasons.お知らせ • Jul 09+ 1 more updateLIDDS Patent Covering the NanoZolid® Production Process Granted in IsraelLIDDS AB (publ) announced that its most recent patent family on the NanoZolid® production process, and hence the achieved pharmaceutical products, hasbeen granted in Israel. The patent provides protection until 2037 in this market. LIDDS has received patent approval in Israel for Patent Application 266008. The invention covering the production process for the NanoZolid® technology provides protection until 2037. Furthermore, the patent protects all pharmaceutical products obtained with the process described in the patent. This adds another important approval for this patent family, which has also received approvals in China, Russia, Australia, India, South Africa, Singapore, South Korea, and Japan in recent times. The patent and a related divisional patent are already approved in the US as previously communicated.お知らせ • Jun 02LIDDS AB (publ) Announces Board ChangesLIDDS AB (publ) at it's annual general meeting held on 1 June 2022 resolved that Max Mitteregger and Johan Lund ware elected as new board members.分析記事 • May 26Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Reported Earnings • May 25First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: kr0.29 loss per share (up from kr0.36 loss in 1Q 2021). Net loss: kr9.75m (loss narrowed 9.6% from 1Q 2021). Revenue missed analyst estimates by 100%. Earnings per share (EPS) also missed analyst estimates by 123%. Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 19% per year.お知らせ • May 12+ 1 more updateLIDDS AB (publ) to Report Q2, 2022 Results on Aug 25, 2022LIDDS AB (publ) announced that they will report Q2, 2022 results on Aug 25, 2022Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Director David Bejker was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Feb 24LIDDS AB (publ) announced that it expects to receive SEK 40.8 million in funding from Nice & Green SALIDDS AB (publ) announced that it has entered into an agreement for private placement of convertible notes for gross proceeds of SEK 40,800,000 on February 22, 2022. The transaction will include participation from Nice & Green SA. The company will receive funding in multiple tranches of SEK 10,200,000 each. The convertible notes have a maturity of 12 months and carries zero interest rate and can be converted into shares at a 7% discount. The transaction is subject to approval from extraordinary general meeting of the company.お知らせ • Feb 22LIDDS AB Next Step with Nanozolid® Formulated DocetaxelLIDDS AB (publ) announced that the next step in the development of NanoZolid®-formulated docetaxel (nanodotax) will be to conduct a short clinical study to understand the immunological effects observed in the Phase I clinical study NZ-DTX-001. In the NZ DTX-001 study, activation of systemic inflammatory biomarkers was observed, which can provide improved conditions for treatment with so-called checkpoint inhibitors and result in treatment effect in non-injected tumors. In the clinical phase I study with nanodotax, which ended in October 2021, an activation of systemic inflammatory biomarkers was observed, which may open up the possibility of a combination therapy with so-called checkpoint inhibitors in cancer immunotherapy. Clinical studies have shown that systemically administered docetaxel significantly improves the response to treatment with checkpoint inhibitors. If LIDDS can show a similar effect with locally administered nanodotax but without systemic side effects, which risk inhibiting the specific immune response against the tumors, both improved efficacy and safety could be achieved. LIDDS has shown in preclinical studies that locally administered nanodotax has as good effect as systemically administered docetaxel but without systemic side effects. In order to provide a better foundation for decision-making in the clinical development of nanodotax, LIDDS has chosen to take over the sponsorship of the previously approved investigator driven trial on prostate cancer patients. The study provides an important analysis opportunity of the immunological response as the included patients will have their prostate surgically removed, which can be analyzed in detail. The study is planned to be conducted at one clinical site and is expected to include ten patients.お知らせ • Dec 30LIDDS AB Announces Positive Topline Results from the Phase I Dose-Escalating Study of NanoZolid-Formulated DocetaxelLIDDS AB announced that the systemic exposure of docetaxel after treating solid tumors with NanoZolid-docetaxel is low and that the study demonstrated activity in both injected lesions and in systemic inflammatory markers. The results support further development of NanoZolid®-docetaxel In October 2021, LIDDS announced the closing of the NZ-DTX-001 Phase I study. It was demonstrated that NanoZolid® in combination with docetaxel was safe and well tolerated, reaching the primary endpoint of the trial. After further analysis it is also concluded that the systemic NanoZolid®-docetaxel exposure is low and that activity in injected lesions is observed. Patients receiving docetaxel showed activation of systemic inflammatory biomarkers including IFN-gamma, CXCL9 and CXCL10. These molecules are considered important for efficient recruitment and activation of immune effector cells and for creating a good environment for treatments with immune-modulating drugs such as check-point inhibitors. LIDDS intends to submit detailed study data for publication in a relevant journal.分析記事 • Dec 15Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...分析記事 • Jul 19Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...分析記事 • Mar 08Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Recent Insider Transactions • Mar 07Director recently bought kr159k worth of stockOn the 5th of March, Daniel Lifveredson bought around 10k shares on-market at roughly kr15.90 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.お知らせ • Mar 04LIDDS AB (publ) Enters R&D Agreement with Potential Exclusive, Global Product License OptionLIDDS AB (publ) announced that an agreement has been signed with Johnson & Johnson Enterprise Innovation Inc. to develop an oncology product based on the NanoZolid® technology for an undisclosed indication. The flexibility of the NanoZolid® technology offers a possibility to develop controlled and sustained release of many different drugs for local application in cancer tumors which improves its efficacy and provides fewer injections and less side effects for the patients.Is New 90 Day High Low • Feb 26New 90-day low: kr13.50The company is down 4.0% from its price of kr14.05 on 27 November 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.お知らせ • Feb 26LIDDS AB (publ) and Pharmidea Signs Manufacturing AgreementLIDDS AB (publ) announced that a collaboration agreement has been signed with PharmIdea SIA in Riga, Latvia. PharmIdea focuses on anti-cancer drugs and sterile formulations. The collaboration enables LIDDS to expand the manufacturing of new product candidates, e.g. including biomolecules and cytostatics, in addition to the already existing collaboration with Recipharm for Liproca Depot. LIDDS is preparing a clinical Phase I trial with intratumoral injections of NZ-TLR9 for treatment of solid tumors in patients with head/neck-, breast cancer, melanoma, sarcomas and lymphomas. The incidence of these cancers is more than 3 million patients yearly. The development of the NZ-TLR9 formulation will be the first project within the collaboration between LIDDS and PharmIdea.お知らせ • Feb 25LIDDS Files Patent Application for Method to Treat Brain Cancer with Intratumoral Depot InjectionsLIDDS AB (publ) announced that a patent application related to NanoZolid® for treatment of brain cancers was filed to the European patent office. The patent application relates to a method to treat brain cancer with intratumoral depots providing a controlled drug release at the tumor site. Advances in treatments of malignant brain tumors have only modestly improved survival rates of patients. LIDDS can with the NanoZolid® technology expand its platform to brain cancer by circumventing the blood-brain barrier and to increase the drug distribution within the tumor area. The application describes treatment methods with NanoZolid® formulations that are administered transcranially with minimally invasive image guided injection techniques to form intratumoral depots that administer substances to the tumor while minimizing damage on the surrounding healthy brain tissue. The NanoZolid® technology can be applied to a large number of relevant active substances.お知らせ • Dec 19LIDDS AB (publ) Provides Update on Chinese Conditional Market Approval (CMA) for Liproca® DepotLIDDS AB (publ) announced that a newly revised guideline from the Chinese National Medical Products Administration (NMPA) has extended the requirements to a full registration dossier for the conditional market approval (CMA). LIDDS licensee Jiangxi Puheng Pharma is therefore aiming to submit the application for CMA for the prostate cancer drug candidate Liproca® Depot in China during first quarter, 2021. The CMA is a faster regulatory pathway for the approval of a medicine that addresses patients’ unmet medical needs based on less comprehensive data than is normally required. The prospect of Puheng Pharma registering Liproca® Depot in China, utilizing the CMA route, would shorten the time to market. Even without a direct approval of the CMA, the official introduction and communication with NMPA will promote the progress of the clinical program and subsequent market approval.お知らせ • Dec 17LIDDS AB (publ) Announces Management Changes, Effective April 19, 2021LIDDS AB (publ) announced that Nina Herne will assume the role of chief executive officer for LIDDS, effective April 19, 2021. Nina Herne has successfully held multiple senior positions in global pharmaceutical companies, most recently at Chiesi Group where she built a biotech operation and managed the company’s Swedish R&D site. Nina brings a wide range of experience from business development and licensing, R&D, operations, strategy development and international stakeholder management from smaller organizations like Zymenex (Managing Director for Sweden and Denmark) and NeuroNova, as well as larger companies like Chiesi, SOBI and NovoZymes (NovoNordisk). Monica will remain as CEO until Nina is in place.分析記事 • Nov 23We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Is New 90 Day High Low • Nov 13New 90-day low: kr13.00The company is down 12% from its price of kr14.80 on 14 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.Is New 90 Day High Low • Oct 29New 90-day low: kr13.10The company is down 6.0% from its price of kr13.95 on 30 July 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 6.0% over the same period.お知らせ • Sep 30LIDDS AB (publ) Announces Data on Liproca Depot from Open Label Extension StudyLIDDS AB (publ) announced results from the voluntary open-label extension (OLE) of LPC-004 in prostate cancer following the Liproca® Depot Phase IIb. Results showed that 50 % of the patients remained at low PSA levels for at least 10 months from their first Liproca® Depot injection and were therefore not treated with a second injection. PSA levels in the remaining six patients were in average reduced by 28% at 2 months post treatment and reduced PSA levels remained in 2 patients at the end of the study with PSA reductions of 43 % and 73 %. The voluntary OLE study involved twelve patients who participated in the Liproca® Depot Phase IIb clinical study. These were to receive a second Liproca® Depot injection, within 6-10 months from the initial injection, when their PSA levels had returned to the pre-study levels. 50 % of the patients (6 of 12) remained at low PSA levels for at least 10 months from their first Liproca® Depot injection and were therefore not treated with a second injection. The patients who received a second Liproca® Depot injection (6 of 12) were followed for another 6 months and their PSA levels were monitored. At 2 months post treatment, PSA levels were in average reduced by 28 %. PSA levels remained reduced over the full study period in 2 of the treated patients - PSA reductions were 43 % and 73 %, respectively.Is New 90 Day High Low • Sep 29New 90-day high: kr16.15The company is up 19% from its price of kr13.60 on 01 July 2020. The Swedish market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 15% over the same period.お知らせ • Jul 10LIDDS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 37.083996 million.LIDDS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 37.083996 million. Security Name: Shares Security Type: Common Stock Securities Offered: 3,090,333 Price\Range: SEK 12 Transaction Features: Rights Offering株主還元LIDDSSE BiotechsSE 市場7D0%-2.2%-1.1%1Y-87.1%20.7%10.5%株主還元を見る業界別リターン: LIDDS過去 1 年間で20.7 % の収益を上げたSwedish Biotechs業界を下回りました。リターン対市場: LIDDSは、過去 1 年間で10.5 % のリターンを上げたSwedish市場を下回りました。価格変動Is LIDDS's price volatile compared to industry and market?LIDDS volatilityLIDDS Average Weekly Movement60.3%Biotechs Industry Average Movement9.9%Market Average Movement6.2%10% most volatile stocks in SE Market14.3%10% least volatile stocks in SE Market3.6%安定した株価: LIDDSの株価は、 Swedish市場と比較して過去 3 か月間で変動しています。時間の経過による変動: LIDDSの 週次ボラティリティ は、過去 1 年間で40%から60%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト19991Mats Wikingwww.liddspharma.comLIDDS AB (publish)はドラッグデリバリー会社で、スウェーデンにおいて、がんやその他の疾患の治療のためにNanoZolid独自技術に基づく医薬品を開発している。同社の製品パイプラインには、前臨床試験中のNanoZolid製剤であるアガトリモド（agatolimod）およびTLR9（toll-like receptor 9）アゴニスト、NanoZolid製剤であるドセタキセル（Nanodotax）、乳がん、頭頸部がん、前立腺がんなど様々ながん治療薬として承認されている化学療法剤、難治性がん治療薬として臨床第Ib/IIa相試験中のNOV202などがある。同社はまた、根治治療前の前立腺がん患者を治療するための抗アンドロゲン薬である2-ヒドロキシルツタミド（2-HOF）をナノゾリド製剤化したリプロカデポも開発している。また、ジョンソン・エンド・ジョンソン エンタープライズ イノベーション社と、NanoZolid技術に基づく非開示の適応症の腫瘍学製品を開発するための研究開発契約を結んでいる。同社は1999年に設立され、スウェーデンのストックホルムを拠点としている。もっと見るLIDDS AB (publ) 基礎のまとめLIDDS の収益と売上を時価総額と比較するとどうか。LIDDS 基礎統計学時価総額SEK 3.36m収益（TTM）-SEK 5.58m売上高(TTM)n/a0.0xP/Sレシオ-0.6xPER（株価収益率LIDDS は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計LIDDS 損益計算書（TTM）収益SEK 0売上原価SEK 3.05m売上総利益-SEK 3.05mその他の費用SEK 2.53m収益-SEK 5.58m直近の収益報告Sep 30, 2025次回決算日Mar 26, 2026一株当たり利益（EPS）-0.041グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%LIDDS の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/16 14:19終値2026/02/09 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋LIDDS AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Ethel Szpilman LuvallRedeye
お知らせ • Nov 20LIDDS AB (publ) to Report Fiscal Year 2025 Final Results on May 06, 2026LIDDS AB (publ) announced that they will report fiscal year 2025 final results on May 06, 2026
Reported Earnings • Sep 03First half 2025 earnings released: kr0.015 loss per share (vs kr0.02 loss in 1H 2024)First half 2025 results: kr0.015 loss per share (improved from kr0.02 loss in 1H 2024). Net loss: kr2.04m (loss narrowed 15% from 1H 2024).
お知らせ • Sep 03LIDDS AB (publ) to Report Fiscal Year 2025 Results on Feb 19, 2026LIDDS AB (publ) announced that they will report fiscal year 2025 results on Feb 19, 2026
お知らせ • Apr 26LIDDS AB (publ), Annual General Meeting, May 28, 2025LIDDS AB (publ), Annual General Meeting, May 28, 2025, at 10:00 W. Europe Standard Time. Location: at excore`s premises, at kungsportsavenyen 22, 411 36 gothenburg Sweden
お知らせ • Feb 20+ 2 more updatesLIDDS AB (publ) to Report Q1, 2025 Results on May 29, 2025LIDDS AB (publ) announced that they will report Q1, 2025 results on May 29, 2025
お知らせ • Nov 22LIDDS AB (publ) to Report Fiscal Year 2024 Final Results on May 06, 2025LIDDS AB (publ) announced that they will report fiscal year 2024 final results on May 06, 2025
お知らせ • Nov 20LIDDS AB (publ) to Report Fiscal Year 2025 Final Results on May 06, 2026LIDDS AB (publ) announced that they will report fiscal year 2025 final results on May 06, 2026
Reported Earnings • Sep 03First half 2025 earnings released: kr0.015 loss per share (vs kr0.02 loss in 1H 2024)First half 2025 results: kr0.015 loss per share (improved from kr0.02 loss in 1H 2024). Net loss: kr2.04m (loss narrowed 15% from 1H 2024).
お知らせ • Sep 03LIDDS AB (publ) to Report Fiscal Year 2025 Results on Feb 19, 2026LIDDS AB (publ) announced that they will report fiscal year 2025 results on Feb 19, 2026
お知らせ • Apr 26LIDDS AB (publ), Annual General Meeting, May 28, 2025LIDDS AB (publ), Annual General Meeting, May 28, 2025, at 10:00 W. Europe Standard Time. Location: at excore`s premises, at kungsportsavenyen 22, 411 36 gothenburg Sweden
お知らせ • Feb 20+ 2 more updatesLIDDS AB (publ) to Report Q1, 2025 Results on May 29, 2025LIDDS AB (publ) announced that they will report Q1, 2025 results on May 29, 2025
お知らせ • Nov 22LIDDS AB (publ) to Report Fiscal Year 2024 Final Results on May 06, 2025LIDDS AB (publ) announced that they will report fiscal year 2024 final results on May 06, 2025
お知らせ • Aug 28LIDDS AB (publ) to Report Fiscal Year 2024 Results on Feb 20, 2025LIDDS AB (publ) announced that they will report fiscal year 2024 results on Feb 20, 2025
お知らせ • May 31LIDDS AB (publ) to Report Nine Months, 2024 Results on Nov 21, 2024LIDDS AB (publ) announced that they will report nine months, 2024 results on Nov 21, 2024
お知らせ • May 29LIDDS AB (publ) to Report First Half, 2024 Results on Aug 28, 2024LIDDS AB (publ) announced that they will report first half, 2024 results on Aug 28, 2024
お知らせ • May 15+ 1 more updateLIDDS AB (publ) Announces CFO Changes, Effective 1 September 2024The Board of Directors of LIDDS AB (publ) appointed Mats Wiking as new CFO from 1 September 2024. Mats Wiking has long financial experience as finance director, controller and business developer from both small and medium sized companies and has the last few years mainly been working with company transactions. Current CFO Jenni Björnulfson will assume a position in another company but will continue in her roles until 1 September 2024 to ensure a smooth transition to Mats Wiking.
New Risk • May 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 100% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr27m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr22.7m market cap, or US$2.09m).
お知らせ • Apr 19LIDDS AB (publ), Annual General Meeting, May 27, 2024LIDDS AB (publ), Annual General Meeting, May 27, 2024.
お知らせ • Mar 22LIDDS AB (publ) (OM:LIDDS) completed the acquisition of Noviga Research AB.LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB on January 29, 2024. The acquisition is subject to approval by the general meeting of LIDDS. The Board of Directors of LIDDS will convene an Extraordinary General Meeting to be held on 27 February 2024. The purchase price consists of newly issued shares in LIDDS in a ratio of 1:1, which means that the number of shares in LIDDS after the transaction amounts to 136,463,326 and value of the transaction is approximately SEK 16.2 million. As of February 27, 2024, LIDDS AB shareholders approved the transaction. LIDDS AB (publ) (OM:LIDDS) completed the acquisition of Noviga Research AB on March 21, 2024.
お知らせ • Jan 30LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB.LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB on January 29, 2024. The acquisition is subject to approval by the general meeting of LIDDS. The Board of Directors of LIDDS will convene an Extraordinary General Meeting to be held on 27 February 2024. The purchase price consists of newly issued shares in LIDDS in a ratio of 1:1, which means that the number of shares in LIDDS after the transaction amounts to 136,463,326 and value of the transaction is approximately SEK 16.2 million.
お知らせ • Jan 09LIDDS AB (publ) Approves Board ElectionsLIDDS AB (publ) at its EGN held on January 9, 2024 approved election of Daniel Lifveredson, Torbjörn Browall and Lars-Inge Sjöqvist as ordinary board members, and Bengt Viterius as deputy board member. Daniel Lifveredson was elected as Chairman of the Board.
お知らせ • Dec 15LIDDS AB (publ) to Report Fiscal Year 2023 Final Results on Apr 23, 2024LIDDS AB (publ) announced that they will report fiscal year 2023 final results at 12:00 PM, Central European Standard Time on Apr 23, 2024
お知らせ • Dec 07Lidds AB (Publ) Announces Resignation of Daniel Lifveredson from Board of DirectorsLIDDS AB (publ) announces that Daniel Lifveredson has informed the company that he is leaving the board at his own request. The decision is based on disagreement about the company's strategic direction. The company's board therefore consists of Pontus Ottosson (chairman), David Bejker and Johan Lund. According to LIDDS' articles of association, the board must consist of a minimum of three and a maximum of ten members, and the board thus fulfills the requirements of the articles of association also after Daniel Lifveredson's resignation.
お知らせ • Nov 29+ 1 more updateLIDDS AB (publ) to Report Q1, 2024 Results on May 15, 2024LIDDS AB (publ) announced that they will report Q1, 2024 results on May 15, 2024
Reported Earnings • Aug 31First half 2023 earnings released: kr0.29 loss per share (vs kr0.58 loss in 1H 2022)First half 2023 results: kr0.29 loss per share (improved from kr0.58 loss in 1H 2022). Net loss: kr17.0m (loss narrowed 14% from 1H 2022). Revenue is expected to decline by 43% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Sweden are expected to grow by 25%.
お知らせ • Aug 01LIDDS AB (publ) Announces CEO ChangesLIDDS AB (publ) announced that Matthew Lindon will assume the role of acting Chief Executive Officer for LIDDS, effective August 1st, 2023, succeeding Anders Månsson. In addition to his role as Chief Scientific Officer for LIDDS, Matthew Lindon will take over the role as CEO on an interim basis from August 1st. Matthew joined LIDDS as CSO in March 2022 with over 20 years of drug discovery and development experience in global pharmaceutical R&D from AstraZeneca, GlaxoSmithKline and Merck. Over the last twelve months he has worked closely with out-going CEO, Anders Månsson to focus LIDDS' business and drive forward a strong business development strategy.Anders will remain with LIDDS until August 31st to ensure a smooth transition.
New Risk • Jul 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr40m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr40m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (96% increase in shares outstanding). Revenue is less than US$1m (kr1.3m revenue, or US$123k). Market cap is less than US$10m (kr33.0m market cap, or US$3.06m).
Reported Earnings • May 30First quarter 2023 earnings released: kr0.29 loss per share (vs kr0.29 loss in 1Q 2022)First quarter 2023 results: kr0.29 loss per share. Net loss: kr9.63m (loss narrowed 1.3% from 1Q 2022). Revenue is expected to decline by 17% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Sweden are expected to grow by 26%.
Reported Earnings • Mar 14Full year 2022 earnings released: kr1.07 loss per share (vs kr1.16 loss in FY 2021)Full year 2022 results: kr1.07 loss per share (improved from kr1.16 loss in FY 2021). Net loss: kr36.9m (loss narrowed 1.1% from FY 2021). Revenue is expected to decline by 1.8% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Sweden are expected to grow by 19%. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
お知らせ • Dec 09LIDDS AB (publ) to Report Fiscal Year 2022 Results on Apr 25, 2023LIDDS AB (publ) announced that they will report fiscal year 2022 results at 12:00 PM, Central European Standard Time on Apr 25, 2023
Reported Earnings • Nov 29Third quarter 2022 earnings released: kr0.23 loss per share (vs kr0.26 loss in 3Q 2021)Third quarter 2022 results: kr0.23 loss per share. Revenue: kr1.19m (up 176% from 3Q 2021). Net loss: kr8.09m (loss widened 3.6% from 3Q 2021).
Reported Earnings • Aug 29Second quarter 2022 earnings released: kr0.29 loss per share (vs kr0.32 loss in 2Q 2021)Second quarter 2022 results: kr0.29 loss per share. Revenue: kr254.0k (up 71% from 2Q 2021). Net loss: kr9.91m (loss widened 1.5% from 2Q 2021).
お知らせ • Aug 26LIDDS AB (publ) to Report Fiscal Year 2022 Results on Feb 24, 2023LIDDS AB (publ) announced that they will report fiscal year 2022 results on Feb 24, 2023
Board Change • Jul 31High number of new directorsIndependent Director Max Mitteregger was the last director to join the board, commencing their role in 2022.
お知らせ • Jul 16LIDDS AB (publ) Announces CEO ChangesLIDDS AB (publ) announced that Anders Månsson will assume the role of Chief Executive Officer for LIDDS, effective September 1st 2022 succeeding Nina Herne. Anders Månsson has broad experience from leading roles both in the biotech sector and in larger multinational pharmaceutical companies in an international setting over 25 years. His substantial experience in business development from serving as e.g VP & Head of Global Business Development in LEO Pharma will be important for LIDDS in driving the value of current and future collaborations. Anders also has considerable experience from sales & marketing; he has been the Managing Director of a subsidiary in Ferring Pharmaceuticals, and he has headed a major global business unit in LEO Pharma. His experience also includes board-level and executive appointments in biotech companies, and most recently Anders was the CEO of RhoVac. Anders will join LIDDS September 1, 2022. Nina will remain as CEO until Anders is in place to secure a smooth transition. Nina is leaving LIDDS due to personal reasons.
お知らせ • Jul 09+ 1 more updateLIDDS Patent Covering the NanoZolid® Production Process Granted in IsraelLIDDS AB (publ) announced that its most recent patent family on the NanoZolid® production process, and hence the achieved pharmaceutical products, hasbeen granted in Israel. The patent provides protection until 2037 in this market. LIDDS has received patent approval in Israel for Patent Application 266008. The invention covering the production process for the NanoZolid® technology provides protection until 2037. Furthermore, the patent protects all pharmaceutical products obtained with the process described in the patent. This adds another important approval for this patent family, which has also received approvals in China, Russia, Australia, India, South Africa, Singapore, South Korea, and Japan in recent times. The patent and a related divisional patent are already approved in the US as previously communicated.
お知らせ • Jun 02LIDDS AB (publ) Announces Board ChangesLIDDS AB (publ) at it's annual general meeting held on 1 June 2022 resolved that Max Mitteregger and Johan Lund ware elected as new board members.
分析記事 • May 26Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Reported Earnings • May 25First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: kr0.29 loss per share (up from kr0.36 loss in 1Q 2021). Net loss: kr9.75m (loss narrowed 9.6% from 1Q 2021). Revenue missed analyst estimates by 100%. Earnings per share (EPS) also missed analyst estimates by 123%. Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 19% per year.
お知らせ • May 12+ 1 more updateLIDDS AB (publ) to Report Q2, 2022 Results on Aug 25, 2022LIDDS AB (publ) announced that they will report Q2, 2022 results on Aug 25, 2022
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Director David Bejker was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Feb 24LIDDS AB (publ) announced that it expects to receive SEK 40.8 million in funding from Nice & Green SALIDDS AB (publ) announced that it has entered into an agreement for private placement of convertible notes for gross proceeds of SEK 40,800,000 on February 22, 2022. The transaction will include participation from Nice & Green SA. The company will receive funding in multiple tranches of SEK 10,200,000 each. The convertible notes have a maturity of 12 months and carries zero interest rate and can be converted into shares at a 7% discount. The transaction is subject to approval from extraordinary general meeting of the company.
お知らせ • Feb 22LIDDS AB Next Step with Nanozolid® Formulated DocetaxelLIDDS AB (publ) announced that the next step in the development of NanoZolid®-formulated docetaxel (nanodotax) will be to conduct a short clinical study to understand the immunological effects observed in the Phase I clinical study NZ-DTX-001. In the NZ DTX-001 study, activation of systemic inflammatory biomarkers was observed, which can provide improved conditions for treatment with so-called checkpoint inhibitors and result in treatment effect in non-injected tumors. In the clinical phase I study with nanodotax, which ended in October 2021, an activation of systemic inflammatory biomarkers was observed, which may open up the possibility of a combination therapy with so-called checkpoint inhibitors in cancer immunotherapy. Clinical studies have shown that systemically administered docetaxel significantly improves the response to treatment with checkpoint inhibitors. If LIDDS can show a similar effect with locally administered nanodotax but without systemic side effects, which risk inhibiting the specific immune response against the tumors, both improved efficacy and safety could be achieved. LIDDS has shown in preclinical studies that locally administered nanodotax has as good effect as systemically administered docetaxel but without systemic side effects. In order to provide a better foundation for decision-making in the clinical development of nanodotax, LIDDS has chosen to take over the sponsorship of the previously approved investigator driven trial on prostate cancer patients. The study provides an important analysis opportunity of the immunological response as the included patients will have their prostate surgically removed, which can be analyzed in detail. The study is planned to be conducted at one clinical site and is expected to include ten patients.
お知らせ • Dec 30LIDDS AB Announces Positive Topline Results from the Phase I Dose-Escalating Study of NanoZolid-Formulated DocetaxelLIDDS AB announced that the systemic exposure of docetaxel after treating solid tumors with NanoZolid-docetaxel is low and that the study demonstrated activity in both injected lesions and in systemic inflammatory markers. The results support further development of NanoZolid®-docetaxel In October 2021, LIDDS announced the closing of the NZ-DTX-001 Phase I study. It was demonstrated that NanoZolid® in combination with docetaxel was safe and well tolerated, reaching the primary endpoint of the trial. After further analysis it is also concluded that the systemic NanoZolid®-docetaxel exposure is low and that activity in injected lesions is observed. Patients receiving docetaxel showed activation of systemic inflammatory biomarkers including IFN-gamma, CXCL9 and CXCL10. These molecules are considered important for efficient recruitment and activation of immune effector cells and for creating a good environment for treatments with immune-modulating drugs such as check-point inhibitors. LIDDS intends to submit detailed study data for publication in a relevant journal.
分析記事 • Dec 15Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Jul 19Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Mar 08Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Recent Insider Transactions • Mar 07Director recently bought kr159k worth of stockOn the 5th of March, Daniel Lifveredson bought around 10k shares on-market at roughly kr15.90 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
お知らせ • Mar 04LIDDS AB (publ) Enters R&D Agreement with Potential Exclusive, Global Product License OptionLIDDS AB (publ) announced that an agreement has been signed with Johnson & Johnson Enterprise Innovation Inc. to develop an oncology product based on the NanoZolid® technology for an undisclosed indication. The flexibility of the NanoZolid® technology offers a possibility to develop controlled and sustained release of many different drugs for local application in cancer tumors which improves its efficacy and provides fewer injections and less side effects for the patients.
Is New 90 Day High Low • Feb 26New 90-day low: kr13.50The company is down 4.0% from its price of kr14.05 on 27 November 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.
お知らせ • Feb 26LIDDS AB (publ) and Pharmidea Signs Manufacturing AgreementLIDDS AB (publ) announced that a collaboration agreement has been signed with PharmIdea SIA in Riga, Latvia. PharmIdea focuses on anti-cancer drugs and sterile formulations. The collaboration enables LIDDS to expand the manufacturing of new product candidates, e.g. including biomolecules and cytostatics, in addition to the already existing collaboration with Recipharm for Liproca Depot. LIDDS is preparing a clinical Phase I trial with intratumoral injections of NZ-TLR9 for treatment of solid tumors in patients with head/neck-, breast cancer, melanoma, sarcomas and lymphomas. The incidence of these cancers is more than 3 million patients yearly. The development of the NZ-TLR9 formulation will be the first project within the collaboration between LIDDS and PharmIdea.
お知らせ • Feb 25LIDDS Files Patent Application for Method to Treat Brain Cancer with Intratumoral Depot InjectionsLIDDS AB (publ) announced that a patent application related to NanoZolid® for treatment of brain cancers was filed to the European patent office. The patent application relates to a method to treat brain cancer with intratumoral depots providing a controlled drug release at the tumor site. Advances in treatments of malignant brain tumors have only modestly improved survival rates of patients. LIDDS can with the NanoZolid® technology expand its platform to brain cancer by circumventing the blood-brain barrier and to increase the drug distribution within the tumor area. The application describes treatment methods with NanoZolid® formulations that are administered transcranially with minimally invasive image guided injection techniques to form intratumoral depots that administer substances to the tumor while minimizing damage on the surrounding healthy brain tissue. The NanoZolid® technology can be applied to a large number of relevant active substances.
お知らせ • Dec 19LIDDS AB (publ) Provides Update on Chinese Conditional Market Approval (CMA) for Liproca® DepotLIDDS AB (publ) announced that a newly revised guideline from the Chinese National Medical Products Administration (NMPA) has extended the requirements to a full registration dossier for the conditional market approval (CMA). LIDDS licensee Jiangxi Puheng Pharma is therefore aiming to submit the application for CMA for the prostate cancer drug candidate Liproca® Depot in China during first quarter, 2021. The CMA is a faster regulatory pathway for the approval of a medicine that addresses patients’ unmet medical needs based on less comprehensive data than is normally required. The prospect of Puheng Pharma registering Liproca® Depot in China, utilizing the CMA route, would shorten the time to market. Even without a direct approval of the CMA, the official introduction and communication with NMPA will promote the progress of the clinical program and subsequent market approval.
お知らせ • Dec 17LIDDS AB (publ) Announces Management Changes, Effective April 19, 2021LIDDS AB (publ) announced that Nina Herne will assume the role of chief executive officer for LIDDS, effective April 19, 2021. Nina Herne has successfully held multiple senior positions in global pharmaceutical companies, most recently at Chiesi Group where she built a biotech operation and managed the company’s Swedish R&D site. Nina brings a wide range of experience from business development and licensing, R&D, operations, strategy development and international stakeholder management from smaller organizations like Zymenex (Managing Director for Sweden and Denmark) and NeuroNova, as well as larger companies like Chiesi, SOBI and NovoZymes (NovoNordisk). Monica will remain as CEO until Nina is in place.
分析記事 • Nov 23We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Is New 90 Day High Low • Nov 13New 90-day low: kr13.00The company is down 12% from its price of kr14.80 on 14 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.
Is New 90 Day High Low • Oct 29New 90-day low: kr13.10The company is down 6.0% from its price of kr13.95 on 30 July 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 6.0% over the same period.
お知らせ • Sep 30LIDDS AB (publ) Announces Data on Liproca Depot from Open Label Extension StudyLIDDS AB (publ) announced results from the voluntary open-label extension (OLE) of LPC-004 in prostate cancer following the Liproca® Depot Phase IIb. Results showed that 50 % of the patients remained at low PSA levels for at least 10 months from their first Liproca® Depot injection and were therefore not treated with a second injection. PSA levels in the remaining six patients were in average reduced by 28% at 2 months post treatment and reduced PSA levels remained in 2 patients at the end of the study with PSA reductions of 43 % and 73 %. The voluntary OLE study involved twelve patients who participated in the Liproca® Depot Phase IIb clinical study. These were to receive a second Liproca® Depot injection, within 6-10 months from the initial injection, when their PSA levels had returned to the pre-study levels. 50 % of the patients (6 of 12) remained at low PSA levels for at least 10 months from their first Liproca® Depot injection and were therefore not treated with a second injection. The patients who received a second Liproca® Depot injection (6 of 12) were followed for another 6 months and their PSA levels were monitored. At 2 months post treatment, PSA levels were in average reduced by 28 %. PSA levels remained reduced over the full study period in 2 of the treated patients - PSA reductions were 43 % and 73 %, respectively.
Is New 90 Day High Low • Sep 29New 90-day high: kr16.15The company is up 19% from its price of kr13.60 on 01 July 2020. The Swedish market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 15% over the same period.
お知らせ • Jul 10LIDDS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 37.083996 million.LIDDS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 37.083996 million. Security Name: Shares Security Type: Common Stock Securities Offered: 3,090,333 Price\Range: SEK 12 Transaction Features: Rights Offering
